Tag: DBV Technologies

Viaskin Peanut

DBV Announces Promising 2-Year Results from Ongoing Viaskin “Peanut Patch” Toddler...

81.3% of subjects who completed the oral food challenge reached an eliciting dose of ≥1,000 mg after 24 months of treatment.
Viaskin Peanut

DBV Outlines Path to Regulatory Approval of Viaskin Peanut Patch

Are Viaskin therapies finally on the horizon?
Viaskin-Patch

FDA Removes Hold Allowing DBV’s Pivotal Phase 3 Peanut Patch Trial...

The phase 3 trial of the modified Viaskin Peanut patch has been cleared for commencement.
Viaskin Patch

Skin Patch Immunotherapy Determined Safe and Effective in Toddlers With Peanut...

According to research presented at this year's #ACAAI22 meeting.
Viaskin Peanut

Private Law Firm to Investigate Claims on Behalf of Investors in...

It is unknown how this development will affect the ability of the company to eventually offer Viaskin Peanut as an FDA approved therapy.
Viaskin Peanut

FDA Issues Partial Hold on DBV Viaskin Peanut Patch Trial

Another delay for the long-awaited therapy.
Viaskin Patch

DBV Begins Phase 3 Study of Redesigned Viaskin Peanut Patch in...

Viaskin is testing a new version of their patch designed to address the FDA's concerns.
Viaskin Patch

DBV Announces Positive Topline Results from Phase 3 Trial of Viaskin...

Viaskin Peanut demonstrated a statistically significant treatment effect with 67.0% of subjects meeting the treatment responder criteria after 12 months.
Viaskin-Patch

Safety of Viaskin Peanut Patch Therapy Improved Over 3-Year Study

Reactions decreased over study duration.
Viaskin Peanut

FDA Wants More Viaskin Peanut Data Resulting in Further Approval Delays

Delays mount pushing trials of modified patch.